Four Core Challenges in Covered Scaffolds for Vascular Devices

Covered scaffolds have long promised the best of both worlds: mechanical support combined with controlled biological interaction. Yet despite decades of innovation, several core challenges continue to limit their performance and long-term outcomes. Understanding these barriers is critical for advancing next-generation vascular implants.

1. Persistent Thrombosis Risk

One of the most stubborn issues with covered scaffolds is their inherent thrombogenicity. Unlike bare-metal or even drug-eluting stents, covered devices introduce a non-endothelialized surface directly into the bloodstream.

This creates a mismatch between the implant and the body’s natural antithrombotic environment. Key contributing factors include:

• Lack of rapid endothelialization across the covering layer

• Flow disturbance at material interfaces and edges

• Surface chemistries that promote protein adsorption and platelet activation

Even when using “biocompatible” polymers like ePTFE or polyurethane, the absence of a functional endothelial layer often leads to prolonged reliance on dual antiplatelet therapy. In high-risk vascular beds, this remains a significant clinical limitation.

2. Ineffective Tissue Integration

Closely related to thrombosis is the challenge of controlled tissue ingrowth. Covered scaffolds are designed to act as barriers, but that same barrier function can inhibit healing.

The ideal outcome is selective integration:

• Endothelialization on the luminal side

• Controlled cellular infiltration on the abluminal side

• Minimal neointimal hyperplasia

In practice, however, many coverings are either:

• Too impermeable, preventing any meaningful biological integration

• Too porous, leading to uncontrolled tissue proliferation and restenosis

Balancing permeability, pore size, and surface chemistry remains an unresolved materials science problem. Attempts to modify surfaces with coatings, bioactive agents, or microstructures have shown promise, but none have fully solved the tradeoff between healing and inhibition.

3. Delamination and Interface Failure

Mechanical integrity is another critical weak point—specifically at the interface between the scaffold and the covering material.

Delamination can occur due to:

• Cyclic mechanical stress from pulsatile blood flow

• Mismatch in elasticity between metal scaffolds and polymer coverings

• Inadequate bonding chemistry or surface preparation

This is particularly problematic in applications involving high flexion or torsion, such as peripheral arteries. Even minor delamination can create flow disruptions, increase thrombogenicity, or lead to device failure.

Advanced bonding strategies,have improved adhesion. However, long-term durability under physiological conditions (moisture, enzymes, fatigue) is still a major concern.

4. The Profile–Deliverability Paradox

Finally, there is the ongoing tradeoff between device performance and deliverability.

Covered scaffolds inherently add material bulk, which increases crossing profile and reduces flexibility. This creates a paradox:

• Thicker, more robust coverings improve durability and reduce leakage

• Thinner coverings improve deliverability but compromise mechanical and barrier properties

In complex anatomies,calcified lesions, tortuous vessels, or small diameters,this tradeoff becomes critical. Devices that perform well in vitro may struggle to reach or properly deploy at the target site.

Efforts to address this include:

• Ultra-thin film technologies

• High-strength, low-thickness polymers

• Novel scaffold geometries that minimize material overlap

Still, achieving both low profile and high performance remains one of the defining engineering challenges in this space.

Covered scaffold technology sits at the intersection of materials science, biomechanics, and vascular biology. While incremental improvements continue, these four challenges: thrombosis, tissue integration, delamination, and deliverability,highlight the need for more integrated design approaches.